Ketamine is under clinical development by Shenox Pharmaceuticals and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketamine (SHX-001) is under development for the treatment of major depressive disorder, Rett syndrome and neuropathic pain. It is administered as transdermal patch. The drug candidate acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA).
Shenox Pharmaceuticals overview
Shenox Pharmaceuticals (Shenox) is a bio pharmaceutical company with focus on the research and development of new drugs with formulations, drug delivery systems, novel combinations and new indications. Its pipeline candidates include SHX-001, SHX-004, SHX-005, SHX-006 and SHX-007 for the treatment of depression; SHX-002 for the management of pain; SHX-008 for the prevention of anaphylaxis (allergic reaction); SHX-003 for treating a rare presynaptic disorder- Lambert–Eaton myasthenic syndrome (LEMS). It seeks to work in partnership with other pharmaceutical companies to enhance the currently available medicines. The company operates a laboratory facility in Guangzhou, China. Shenox is headquartered in North Brunswick, New Jersey, the US.
For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.